The First FDA-Cleared
Indication Specifically for
Thyroid Nodule RFA
in the United States
After 300+ clinical studies on thyroid RFA, STARMED has achieved what no other company has: the first FDA indication for RFA of thyroid nodules in the U.S. The most clinically proven system in the field, now with the clearance to match.
Creating better outcomes
for patients everywhere
We are committed to improving the way tumors are treated through less invasive, organ-preserving solutions that put patients first.

